Shire/Noven Resubmit ADHD Patch Application
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire/Noven's resubmission for a methylphenidate transdermal system will receive a six month review at FDA, Shire said July 26
You may also be interested in...
Shire/Noven Methypatch For ADHD To Be Reviewed By Psychopharm Committee
Companies seek indication for once-daily methylphenidate patch for the treatment of attention deficit/hyperactivity disorder in children ages six to 12 years.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.